# Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients

Study · id `cardio:ct-nct01439009` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01439009](<https://clinicaltrials.gov/study/NCT01439009>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01439009

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT01439009. Randomized; quadruple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2014-03 (actual). Results posted on 2019-10-22.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT01439009, source copy `cardio:ctgov-nct01439009-2019-10-22`, retrieved 2026-10-26)
- Start date: 2011-09 (registry gives no type) (ClinicalTrials.gov record NCT01439009, source copy `cardio:ctgov-nct01439009-2019-10-22`, retrieved 2026-10-26)
- Primary completion: 2014-03 (actual) (ClinicalTrials.gov record NCT01439009, source copy `cardio:ctgov-nct01439009-2019-10-22`, retrieved 2026-10-26)
- Completion: 2014-03 (actual) (ClinicalTrials.gov record NCT01439009, source copy `cardio:ctgov-nct01439009-2019-10-22`, retrieved 2026-10-26)
- Results first posted: 2019-10-22 (ClinicalTrials.gov record NCT01439009, source copy `cardio:ctgov-nct01439009-2019-10-22`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01439009, source copy `cardio:ctgov-nct01439009-2019-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01439009-2019-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients
- Condition: Heart Failure
- Intervention (Drug): Tolvaptan
- Intervention (Drug): Placebo of tolvaptan
- Lead sponsor: Otsuka Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Otsuka Pharmaceutical Co., Ltd. (`cardio:org-otsuka-pharmaceutical-co-ltd`)

## Provenance

Content hash: 2330b29b7d42de85b12bf211dc04d1d6b78eb9575a90f8c295beb64ed3e3b322
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
